Board of Managers
Ronald Lennox
Dr. Lennox has been a board member of Thetis since 2018. He has invested broadly in the life science sector with an emphasis on biotechnology and molecular diagnostics. He is currently CEO of Monogram Orthopaedics, Inc., a spin-out from Mount Sinai School of Medicine where he also serves as an Entrepreneur in Residence. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding Chairman of Amicus Therapeutics (NASDAQ: FOLD, another Mount Sinai spin-out), Chairman of Bikam Therapeutics where he managed its sale to Shire in 2014, and founding CEO of two Yale start-ups, Protometrix, Inc. and CGI Pharmaceuticals, Inc (acquired by Gilead Sciences, Inc.). He was one of the three founding partners of CHL Medical Partners, and prior to that was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs. Dr. Lennox graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania where he received his MBA.
Ronald Lennox, D.Phil
Independent Board Member
Gary Mathias
Co-Founder and Chief Executive Officer
Mr. Mathias has more than 30 years of experience in the healthcare industry as an entrepreneur, investor and banker. Over the course of his career, he has raised over $250 million in debt and equity for pharmaceutical and healthcare companies. Prior to co-founding Thetis, Mr. Mathias was Managing Director and Healthcare Group Lead at Carter Morse & Mathias, SVP in the Healthcare Group of GE Equity Capital, Chief Operating Officer of Diabetes Support Systems, and EVP of Premier Healthcare, a healhcare private equity firm. Mr. Mathias has a bachelor's degree in economics from Harvard College, an MBA from the Yale School of Management, and was a Fulbright Fellow in Colombia, South America.
Gary Mathias
Co-Founder and CEO
Walter Ogier
Mr. Ogier has been an advisor to Thetis since 2012 and joined the board in 2016. He has more than 30 years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies and gene therapies. He has served in multiple CEO roles including Genetix Pharmaceuticals, Inc. (now bluebird bio, Inc.) and Acetylon Pharmaceuticals, Inc., which Celgene Corporation acquired in 2016. He also current is a director of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), Biothera Pharmaceuticals, Inc., and Nemucore Medical Innovations, Inc., and as Board advisor to Kodikaz Therapeutic Solutions, Inc., and ME Therapeutics, Inc. Mr. Ogier earned a Master of Business Administration from Yale School of Management and a Bachelor of Arts in Chemistry from Williams College.
Walter Ogier
Independent Board Member
Frank C. Sciavolino, PhD
Co-Founder, President and CSO
Dr. Sciavolino has extensive experience in the pharmaceutical industry, including a distinguished 35 year career at Pfizer Global R&D. At Pfizer, Dr. Sciavolino held various management roles and responsibilities in drug discovery, development, registration and licensing, culminating in a role as Vice President of R&D Operations, in which he oversaw a team of 1,000 scientists in the United States, Europe and Asia. He was the enabling force behind two of Pfizer’s most notable franchises, Zithromax and Celebrex. After leading the discovery chemistry team responsible for the initial macrolide antibiotic research, he served as principal investigator leading the Phase I evaluation of 11 compounds in first-in-human (FIH) studies, which led to the identification and development of Zithromax, an antibiotic considered one of the most important new drugs of the 20th century. He also played a major role in the licensing of Celebrex, a COX-2 inhibitor that reached $3 billion in peak annual sales globally.
Dr. Sciavolino has served on numerous editorial boards including Annual Reports in Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and the Journal of Antibiotics. Dr. Sciavolino has more than 30 issued patents and has a Ph.D. in organic chemistry from the University of Michigan and B.S. in Pharmacy from St. John’s University.
Frank C. Sciavolino, PhD
Co-Founder and CSO Emeritus
Dennis Willson, JD
Mr. Willson has been a board member of Thetis since 2012. He previously was President & CEO of ITF Pharma, Inc. and co-founder and chairman of Hsiri Therapeutics, LLC, a start-up company focused on the development of new antibiotics for drug-resistant infections. Prior to his time at ITF, he was co-founder, President & CEO of Cytokine PharmaSciences, Inc., a biopharmaceutical company focused on women’s health, inflammation and cancer. Mr. Willson spent 19 years in leadership positions at Cytokine, managing the successful development and licensing of several products, including Cervidil, one of the world’s leading obstetric products. In October 2011, he led the company in a strategic sale to Ferring S.A.
Before joining Cytokine, Mr. Willson held management, finance and business development positions at Abbott Laboratories, Rorer International, and Carrington Laboratories. Mr. Willson graduated summa cum laude from the University of Notre Dame with a degree in psychology and modern languages and has a law degree from the University of California, Hastings College of the Law.
Dennis Willson
Independent Board Member